Vancouver, British Columbia–(Newsfile Corp. – February 24, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (“ Entheon” or the “Company“), a biotechnology company focused on developing psychedelic medicines to treat addiction, provides a production update on HaluGen Life Sciences Inc. (“HaluGen“), a wholly-owned subsidiary of Entheon, which is in the business of developing and…


Previous articleNeonMind Purchases GMP Grade Synthetic Psilocybin from Psygen Labs for Phase 2 Human Clinical Trial
Next articleRed Light Holland Announces Closing of $11.6 Million Bought Deal Financing